196
Participants
Start Date
December 31, 2010
Primary Completion Date
May 31, 2012
Study Completion Date
September 30, 2012
Placebo
Tablets, oral, 0 mg, once daily, for 24 weeks
Daclatasvir
Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks
Pegylated interferon alfa-2a
Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks
Ribavirin
Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks
Local Institution, Darlinghurst
Local Institution, Westmead Nsw
Local Institution, Hvidovre
Local Institution, Clayton Vic
Local Institution, Adelaide
Local Institution, Fremantle
Digestive Disease Associates, P.A., Baltimore
Local Institution, Brescia
Local Institution, Pessac
Local Institution, Montpellier
Local Institution, Cisanello (pisa)
Local Institution, Lille
Options Health Research, Llc, Tulsa
Local Institution, Paris
Alamo Medical Research, San Antonio
California Liver Institute, Los Angeles
Local Institution, Créteil
Local Institution, Camperdown
Local Institution, Calgary
Local Institution, Edmonton
Local Institution, Vancouver
Local Institution, Victoria
Local Institution, Winnipeg
Local Institution, Toronto
Local Institution, Nice
Local Institution, Viale Del Policlinico, 155
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY